title: Long-term evaluation of chromosomal breakages after radioisotope synovectomy for treatment of target joints in patients with haemophilia.
abstract: Radioisotope synovectomy (RS) is defined as the intra-articular injection of radioisotopic agents with the aim of fibrosis on hypertrophic synovium in the target joint. The aim of this study was to investigate genotoxic effects on lymphocytes and malign transformation induced by Yttrium(90) (Y(90)) and Rhenium(186) (Re(186)) in children with haemophilia undergone RS. Forty haemophilia patients were enrolled. The mean age was 16.4 +/- 6.2 years (range: 8-40). Y(90) was used for knees, Re(186) was used for other joints. For safety, cytogenetic analysis was performed to determine potential chromosomal changes after RS procedure at three different time points as prior to procedure, 3rd day and 90th day. For the stimulation of chromosomal breakages, diepoxybutane was used (DEB test). Chromosomal breakages (CBs) were found in 23 patients (67.6%) prior to RS. We have found CBs additionally in nine of 11 patients who had no CBs prior to RS after 3 days of radioisotope exposure. At that time, the patients who had CBs were 29 (85.2%). At day 90, only 21 patients revealed (61.7%) CBs. The mean frequency of CBs slightly but not significantly increased in the 3rd day. However, there was a significant decreasing trend between 3rd and 90th days. Radioisotope synovectomy with Y(90) and Re(186) does not seem to induce the genotoxic effects significantly on peripheral blood lymphocytes. However, CBs even after one year in the re-evaluation of four patients, significant decrease in the number of CBs between the 3rd and 90th days and de novo CBs after exposure may be accepted as warning signals for young population. It should also be pointed out that families and patients be informed properly related with historical and potential dangers of radioisotopic agents.
authors.affiliation: Department of Pediatric Hematology, Ege University, Faculty of Medicine, Izmir, Turkey. kaan.kavakli@ege.edu.tr
authors.forename: K
authors.initials: K
authors.lastname: Kavakli
authors.forename: O
authors.initials: O
authors.lastname: Cogulu
authors.forename: S
authors.initials: S
authors.lastname: Aydogdu
authors.forename: H
authors.initials: H
authors.lastname: Ozkiliç
authors.forename: B
authors.initials: B
authors.lastname: Durmaz
authors.forename: O
authors.initials: O
authors.lastname: Kirbiyik
authors.forename: F
authors.initials: F
authors.lastname: Ozkinay
authors.forename: C
authors.initials: C
authors.lastname: Balkan
authors.forename: D
authors.initials: D
authors.lastname: Karapinar
authors.forename: Y
authors.initials: Y
authors.lastname: Ay
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D019457:Chromosome Breakage; D005260:Female; D006395:Hemarthrosis / Q000517:prevention & control / Q000532:radiotherapy; D006467:Hemophilia A / Q000150:complications / Q000235:genetics* / Q000532:radiotherapy*; D002836:Hemophilia B / Q000150:complications / Q000235:genetics* / Q000532:radiotherapy*; D006801:Humans; D007270:Injections, Intra-Articular; D008214:Lymphocytes / Q000528:radiation effects; D008297:Male; D011446:Prospective Studies; D011868:Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000009:adverse effects* / Q000627:therapeutic use; D012211:Rhenium / Q000009:adverse effects; D014170:Transformation, Genetic; D055815:Young Adult; D015021:Yttrium Radioisotopes / Q000009:adverse effects
chemical_list: D011868:Radioisotopes; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D012211:Rhenium